SVB Wealth LLC Trims Stake in Johnson & Johnson $JNJ

SVB Wealth LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 8.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,463 shares of the company’s stock after selling 2,761 shares during the period. SVB Wealth LLC’s holdings in Johnson & Johnson were worth $5,649,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Clayton Financial Group LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Compass Financial Services Inc boosted its position in shares of Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares in the last quarter. Finally, Signature Resources Capital Management LLC grew its stake in shares of Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.6%

JNJ opened at $238.62 on Tuesday. The stock has a market capitalization of $574.90 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 2.33 and a beta of 0.35. The firm has a 50 day moving average price of $214.20 and a 200-day moving average price of $194.70. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $240.93. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The business had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. HSBC upped their price target on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Finally, Argus raised their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.